Monoclonal antibodies (mAbs) against PD-1/PD-L1 show satisfying overall survival (OS) in melanoma and non-small cell lung cancer (NSCLC), but there is limited survival benefit in glioma (12). This evidence concerns the gene CD274 and non-small cell lung carcinoma.